ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
87.61
+0.65 (+0.75%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close86.96
Open86.67
Bid87.00 x 800
Ask90.50 x 4000
Day's Range84.60 - 87.88
52 Week Range77.50 - 125.86
Volume5,229,396
Avg. Volume6,386,425
Market Cap131.785B
Beta (3Y Monthly)1.79
PE Ratio (TTM)18.30
EPS (TTM)4.79
Earnings DateJan 24, 2019 - Jan 28, 2019
Forward Dividend & Yield4.28 (4.74%)
Ex-Dividend Date2019-01-14
1y Target Est100.33
Trade prices are not sourced from all markets
  • AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
    Zacks6 hours ago

    AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day.

  • InvestorPlace14 hours ago

    Don’t Punish Gilead Stock for Doing Its Job

    In a turbulent year for Gilead Sciences (NASDAQ:GILD), the company recently generated headlines that will hopefully turn things around for GILD stock. Over the weekend, insider information pegged Roche Holdings (OTCMKTS:RHHBY) executive Daniel O’Day as its new CEO. O’Day is no stranger to the industry, having served as Roche Pharmaceuticals’ chief executive since June 3, 2016.

  • Humira’s Biosimilar Competition in International Markets
    Market Realist14 hours ago

    Humira’s Biosimilar Competition in International Markets

    AbbVie (ABBV) expects Humira to report revenue of close to $6.3 billion in international markets in 2018. AbbVie reported Humira sales worth $1.58 billion in international markets in the third quarter, YoY (year-over-year) rises of 1.8% on a reported basis and 4.2% on an operational basis.

  • Zacks15 hours ago

    Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend

    Amgen (AMGN) hikes its quarterly dividend by 10%.

  • Considering AbbVie’s 2018 Expense Projections
    Market Realist15 hours ago

    Considering AbbVie’s 2018 Expense Projections

    In the third quarter, AbbVie (ABBV) reported SG&A (selling, general, and administrative) expenses of $1.57 billion, a YoY (year-over-year) rise of 8.77%. However, its adjusted SG&A as a percentage of its total revenue was 19.1% in the third quarter, a YoY improvement of 170 basis points. According to AbbVie’s third-quarter earnings conference call, the company benefited from improved operational efficiencies and sales leverage in the quarter.

  • Exploring AbbVie’s Margin Projections for 2018
    Market Realist17 hours ago

    Exploring AbbVie’s Margin Projections for 2018

    On its third-quarter earnings conference call, AbbVie (ABBV) said that it expected its gross margin ratio for 2018 to be more than 80.5% and its adjusted operating margin to be close to 45%. In the third quarter, AbbVie reported an adjusted gross margin of 81.7%, a YoY (year-over-year) rise of 90 basis points. It expects a further positive impact of 170–180 basis points on its gross margin in 2019 due to the royalty termination.

  • Here's Why AbbVie Stock Surged 21.1% in November
    Motley Foolyesterday

    Here's Why AbbVie Stock Surged 21.1% in November

    Hints of success for the company's blood cancer pipeline encouraged investors last month.

  • 3 Top Stocks to Buy in December
    Motley Fool2 days ago

    3 Top Stocks to Buy in December

    These stocks have one common denominator: Great long-term growth prospects.

  • Did Gilead Sciences Make an $11 Billion Blunder?
    Motley Fool2 days ago

    Did Gilead Sciences Make an $11 Billion Blunder?

    Spoiler alert: The answer is "no."

  • Is AbbVie Inc (ABBV) A Good Stock To Buy?
    Insider Monkey2 days ago

    Is AbbVie Inc (ABBV) A Good Stock To Buy?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]

  • A Look at AbbVie’s Earnings Projections for 2018
    Market Realist3 days ago

    A Look at AbbVie’s Earnings Projections for 2018

    On its third-quarter earnings conference call, AbbVie (ABBV) raised its adjusted EPS guidance for 2018 from its previous projection of $7.76–$7.86 to $7.90–$7.92. The revised estimate implies a YoY (year-over-year) rise of 41.3% considering the midpoint of the guidance range. As per the company’s third-quarter earnings conference call, AbbVie expects its adjusted fourth-quarter EPS to be in the range of $1.89–$1.91 excluding a $0.26 impact of noncash amortization and other items.

  • Assessing AbbVie’s 2018 Revenue Projections
    Market Realist3 days ago

    Assessing AbbVie’s 2018 Revenue Projections

    On its third-quarter earnings conference call, AbbVie (ABBV) raised its net revenue guidance for 2018 from its previous projection of $32.5 billion to $32.7 billion. The company also raised its forecast for YoY (year-over-year) operational revenue growth in 2018 from 14.5% to 15.0%. As per AbbVie’s third-quarter earnings conference call, the company expects a favorable revenue impact of less than 1% due to foreign currency fluctuations in 2018.

  • Analysts’ Recommendations for AbbVie in December
    Market Realist3 days ago

    Analysts’ Recommendations for AbbVie in December

    The company saw a rise of 17.53% in its share price from $80.21 on November 1 to $94.27 on November 30. Thereafter, AbbVie saw a 3.95% fall in its share price from November 30 to December 5. On November 30, AbbVie issued a press release announcing agreements that granted Pfizer (PFE) a nonexclusive global license related to Humira’s intellectual property.

  • Investing.com3 days ago

    AbbVie Falls 4%

    Investing.com - AbbVie (NYSE:ABBV) fell by 4.11% to trade at $86.620 by 11:29 (16:29 GMT) on Friday on the NYSE exchange.

  • The Wall Street Journal4 days ago

    [$$] Congress to Drug Makers: Why Stock Buybacks Over Lowered Drug Prices?

    Critics of high drug prices are launching a new line of attack against manufacturers of the medicines, faulting the firms for using savings from the tax overhaul to buy back shares rather than lower prices. The attacks began in October, when more than a dozen Democrats in the House of Representatives sent letters to five big pharmaceutical companies saying they had benefited from recent tax cuts but kept charging high prices. The letters singled out certain drugs whose list prices had increased and asked their manufacturers for details about price changes and the costs of research and advertising.

  • InvestorPlace5 days ago

    AbbVie Stock Has a $10 Upside Opportunity — Buy It Now

    In the last five years, AbbVie (NYSE:ABBV) stock is up 76%, which is impressive. Coming into today, AbbVie is down 5% in a year. The fundamentals, although very strong, are under attack from headlines about tariff wars especially between the United States and China.

  • Investing.com4 days ago

    AbbVie Falls 3%

    Investing.com - AbbVie (NYSE:ABBV) fell by 3.25% to trade at $87.610 by 11:27 (16:27 GMT) on Thursday on the NYSE exchange.

  • AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
    Zacks5 days ago

    AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

    IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.

  • Benzinga5 days ago

    The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

    Here's a roundup of top developments in the biotech space over the past 48 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 4) Johnson & Johnson (NYSE: JNJ ) Eli Lilly And Co (NYSE: ...

  • Reuters5 days ago

    AbbVie halts late-stage trial for lung cancer drug Rova-T

    AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee. The committee's recommendations were based on shorter overall survival in the Rova-T arm, compared with the topotecan control arm, the company said. AbbVie acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as the company aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its arthritis treatment Humira, the world's top selling drug.

  • Gilead's (GILD) Harvoni and Descovy Get Approval in China
    Zacks5 days ago

    Gilead's (GILD) Harvoni and Descovy Get Approval in China

    Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.

  • Why Oregon can now afford to treat more people with hepatitis C
    American City Business Journals5 days ago

    Why Oregon can now afford to treat more people with hepatitis C

    While a course of treatment once came close to $100,000, new drugs have emerged to bring the price tag way down.

  • PR Newswire5 days ago

    Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

    - Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped NORTH CHICAGO, Ill. , Dec. 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based ...